Aller au contenu principal
Accès ouvert déclaré 2024 dataset

Additional file 1 of ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Additional file 1: Fig. S1. Prognostic significance of ARGs in OC patients. A Prognostic models were constructed by LASSO regression based on ARGs. B Lambda on abscissa, coefficients on ordinate. C The survival times, risk score, and signature expression in OC patients. D Overall survival analysis for OC patients with high or low risk. E ROC curves for survival analysis. F Correlation analysis between the risk score and immune cell infiltration. *P < 0.05, **P < 0.01, ***P < 0.001. Fig. S2. Hub prognostic ARGs in OC. Uni_cox (A) and Mult_cox (B) for 13 signatures in OC. Overall survival significance confirmed by the nomogram (C) and calibration curve (D). Drug sensitivity analysis for EGF, ANGPTL4, RUNX1, PLG, and NOTCH4 in the CTRP database (E) and GDSC database (F). PCR analysis (G) for the level of ANGPTL4 and ESM1 in SKOV3 treated with different doses of bevacizumab *P < 0.05, **P < 0.01, ***P < 0.001. Fig. S3. The expression of ANGPTL4 in pan-carcinoma based TCGA database and GTEx database. The blue is for normal tissue samples and the red is for cancer samples. Fig. S4. The expression of downstream genes in HeyA8 cells after ANGPTL4 overexpression. A ANGPTL4 expression confirmed in Hey-A8 cells by IF staining. B Volcano plot for DEG expression after ANGPTL4 overexpression by RNA sequencing. C Heatmaps for DEG expression. D GSVA analysis and E KEGG analysis for 14 DEGs. Fig. S5. The level of free ANGPTL4 in CM. Free ANGPTL4 expression confirmed in the CM of SKOV3 and Hey-A8 cells by ELISA. *P < 0.05. Fig. S6. ESM1 was a key factor in the downstream of JAK-STAT pathway. A The expression of ESM1 in SKOV3-DMSO, SKOV3-Colivelin, Hey-A8-DMSO, and Hey-A8-AG490 groups. B The effect of ESM1 on the angiogenesis ability of OC induced by JAK inhibitor/activator. C The effect of ANGPTL4 on ESM1 expression. D Co-IP showed the effects of JAK activator Colivelin on the interaction between ANGPTL4 and ESM1 in SKOV3 cells. Fig. S7. The ANGPTL4/ESM1 axis promotes OC growth and angiogenesis in vivo. A Morphological observation, HE and IHC staining of xenografts in the vector-SKOV3, ANGPTL4 KD-SKOV3, ANGPTL4 KD-SKOV3 with ESM1 OE, vector-HeyA8, ANGPTL4 OE-HeyA8, and ANGPTL4 OE-HeyA8 with ESM1 OE groups. B The tumor weight and volume and the IHC staining score of xenografts in the vector-SKOV3, ANGPTL4 KD-SKOV3, ANGPTL4 KD-SKOV3 with ESM1 OE, vector-HeyA8, ANGPTL4 OE-HeyA8, and ANGPTL4 OE-HeyA8 with ESM1 OE groups. *P < 0.05.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

La source scientifique ouverte est momentanément indisponible.

Où se fait cette recherche

  • Zhuzhou Central Hospital pays non établi dans la notice
    Établissement de santé
  • University of South China pays non établi dans la notice
    Université ou école supérieure
  • Central South University pays non établi dans la notice
    Université ou école supérieure

Zhuzhou Central Hospital, University of South China et Central South University.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Lipid metabolism and disordersApelin-related biomedical researchKruppel-like factors research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.